




INTERA 3000™
Hepatic Artery Infusion Pump


**Boston
Scientific**
Advancing science for life™



Difference **delivered.**

Hepatic Artery Infusion Therapy


Liver-directed therapy to treat colorectal cancer liver metastases (CRLM) and intrahepatic cholangiocarcinoma (iCCA).



Offered in 85% of the top 50 cancer centers.¹ And growing.

Multidisciplinary care teams across the country are adding HAI therapy to traditional systemic chemotherapy to achieve treatment goals, including liver disease control and conversion to eligibility for surgical resection.^{2,3,4,5}

Your difference maker.



Compared to systemic therapy alone, there's no comparison.

The HAI therapy difference shows up in both the data and the scans.

Colorectal Cancer Liver Metastases Outcomes

Doubled median OS in isolated unresectable CRLM

33 months in patients treated with HAI therapy + systemic chemotherapy
vs.
15 months in patients treated with systemic chemotherapy alone.³

Adjuvant Application for CRLM recurrence prevention

Using HAI therapy with systemic chemotherapy has been shown to improve OS at every milestone.^{4,9}
60% improvement in 10-year OS compared to systemic chemotherapy alone.⁹

Intrahepatic Cholangiocarcinoma Outcomes


A radical shift for patients with advanced unresectable liver-confined iCCA

32% 3-year OS for patients treated with HAI therapy + systemic chemotherapy.⁵

BEFORE



Spot the difference.




AFTER

Example of an unresectable patient before and after HAI therapy administration.

It's time to add HAI therapy to your liver program.

Discover the multidisciplinary approach to managing HAI therapy for your patients with colorectal cancer liver metastases (CRLM) and intrahepatic cholangiocarcinoma (iCCA).



Add HAI therapy to your liver program.

Reach out to your Boston Scientific sales representative.



View important safety information.

Indications, contraindications, warnings, precautions, adverse events. View HAI therapy safety information.

References

1. U.S. News & World Report. 2025-26 "Best Hospitals: Cancer." Health; cited 2025 Nov 12.
2. Pak L, et al. J Surg Oncol. 2018;117(4):634-643.
3. Dhir M, et al. Ann Surg Oncol. 2017;24(1):150-158.
4. Kemeny N, et al. N Engl J Med. 1999;341(27):2039-48.
5. Franssen, et al. Journal of Clinical Oncology 2025, JCO-25-00923, DOI:10.1200/JCO-25-00923.
6. Enslinger WD, Gyves JW. Semin Oncol. 1983;10(2):176-82.
7. Holster J, et al. Ann Surg Oncol, 2022;29(9):5528-5538.
8. Cowzer D, et al. J Natl Cancer Inst. 2025;117(2):279-286.
9. Groot Koerkamp B, et al. J Clin Oncol. 2017; 35(17): 1938-1944.

Boston Scientific

Advancing science for life™

Interventional Oncology and Embolization

300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI-2423806-AA